(Q30912454)

27 June 2017

1 reference

title

New antifungal agents: voriconazole and caspofungin (English)

1 reference

27 June 2017

1 reference

B Dupont

1

1 reference

PubMed ID

15022787

27 June 2017

language of work or name

French

0 references

publication date

1 December 2003

1 reference

27 June 2017

Archives de Pediatrie

1 reference

27 June 2017

10 Suppl 5

1 reference

27 June 2017

592s-598s

1 reference

International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia

27 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Review of the safety and efficacy of voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Voriconazole: a new triazole antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

1 reference

7 January 2021

Caspofungin: the first representative of a new antifungal class.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2803%2990043-1

7 January 2021

10.1016/S0929-693X(03)90043-1

Identifiers

DOI

1 reference

27 June 2017

1 reference

PubMed ID

15022787